CAR-T Meeting 2024 | CAR-T vs bispecifics in triple-class refractory multiple myeloma: comparing outcomes & sequencing
Borja Puertas-Martinez, MD, University Hospital of Salamanca, Salamanca, Spain, discusses a study that aimed to compare the outcomes of patients with triple-class refractory multiple myeloma (MM) treated with CAR T-cell therapy to those treated with bispecific antibodies. Patients in the CAR-T group achieved higher response rates, however this did not translate to a greater progression-free survival (PFS) than the bispecific antibody group. Overall survival (OS) was greater in the patients treated with CAR-T. Salvage therapies used in these patients were investigated to understand the possible reasons for this. CAR-T therapy followed by bispecific antibodies resulted in the greatest survival benefit, however, Dr Puertas-Martínez highlights that data were not available to investigate whether bispecifics followed by CAR-T would result in comparable outcomes. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
